For SARS-CoV2 infection and a potential treatment for Sepsis

Discovery Optimisation Pre-clinical Phase 1 Phase 2

Small molecule, peptide combination treatment, VAL201 peptide repurposed for anti-inflammatory use in combination with complementary generic components.

Primary indication: Hyperimmune response in patients after SARS-CoV2 infection

Follow-up indications: Sepsis

Patents: PCT patent family application WO/2021/244964

Developed by: Black Cat Bio Limited in partnership with Oncolytika and ValiRx

Black Cat Bio logo

Oncolytika logo